| Diabetes Mellitus, Non-Insulin-Dependent
Invokana vs Ozempic
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Invokana vs Ozempic with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOzempic has a higher rate of injection site reactions vs Invokana based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ozempic but not Invokana, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Invokana
Ozempic
At A Glance
Oral
Once daily
SGLT2 inhibitor
SC injection
Once weekly
GLP-1 receptor agonist
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
- Chronic Kidney Diseases
Dosing
Diabetes Mellitus, Non-Insulin-Dependent (glycemic control) 100 mg orally once daily before the first meal of the day; may increase to 300 mg once daily in patients tolerating 100 mg with eGFR >= 60 mL/min/1.73 m2 who require additional glycemic control.
Cardiovascular risk reduction, Diabetic nephropathy 100 mg orally once daily.
Diabetes Mellitus, Non-Insulin-Dependent Start 0.25 mg SC once weekly for 4 weeks, increase to 0.5 mg once weekly; escalate to 1 mg then 2 mg based on glycemic control (max 2 mg once weekly).
Chronic Kidney Diseases Start 0.25 mg SC once weekly for 4 weeks, increase to 0.5 mg once weekly; maintenance dose is 1 mg once weekly.
Contraindications
- Serious hypersensitivity reaction to canagliflozin or any excipient, such as anaphylaxis or angioedema
- Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
- Serious hypersensitivity reaction to semaglutide or any excipient in Ozempic
Adverse Reactions
Most common (>=2%) Urinary tract infections, increased urination, thirst, constipation, nausea, female genital mycotic infections, vulvovaginal pruritus, male genital mycotic infections
Serious Diabetic ketoacidosis, lower limb amputation, volume depletion, urosepsis and pyelonephritis, hypoglycemia with concomitant insulin or insulin secretagogues, necrotizing fasciitis of the perineum (Fournier's gangrene), hypersensitivity reactions, bone fracture
Postmarketing Ketoacidosis, acute kidney injury, anaphylaxis, angioedema, urosepsis and pyelonephritis, necrotizing fasciitis of the perineum (Fournier's gangrene)
Most common (>=5%) Nausea, vomiting, diarrhea, abdominal pain, constipation
Serious Risk of thyroid C-cell tumors, acute pancreatitis, diabetic retinopathy complications, hypoglycemia with insulin secretagogues or insulin, acute kidney injury, severe gastrointestinal reactions, hypersensitivity reactions, acute gallbladder disease, pulmonary aspiration
Postmarketing Ileus, intestinal obstruction, severe constipation, fecal impaction, anaphylaxis, angioedema, rash, urticaria, cholecystitis, cholecystectomy, dysesthesia, headache, pulmonary aspiration, acute kidney injury, alopecia
Pharmacology
SGLT2 inhibitor; canagliflozin inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and lowering the renal threshold for glucose, thereby increasing urinary glucose excretion; also blocks SGLT2-dependent sodium reabsorption, believed to increase tubuloglomerular feedback and reduce intraglomerular pressure.
Semaglutide is a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, stimulating insulin secretion and lowering glucagon secretion in a glucose-dependent manner, with a minor delay in gastric emptying; prolonged half-life is achieved through albumin binding, which reduces renal clearance and protects against metabolic degradation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Invokana
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (11/12)
Ozempic
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Invokana
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Ozempic
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Invokana
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Ozempic
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health Heart Failure Patient Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$25/momo
Ozempic Savings Program - Covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
InvokanaView full Invokana profile
OzempicView full Ozempic profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.